Skip to main content
SpringerLink
Log in

Clinicopathological characters of triple negative breast cancer

  • Original Article
  • Published:
Chinese Journal of Cancer Research

Abstract

Objective

To study the clinicopathological characters of triple negative breast cancer (TNBC).

Methods

A total of 629 patients with breast cancer were reviewed, who were treated from 2003 to 2007 in Chongqing Cancer Institute. The comparison of clinicopathological features including TNM classification, histological type, tumor location, axillary lymphonodes status and neoadjuvant chemotherapy between TNBC and nontriple negative breast cancer (NTNBC) was performed. The overall response was evaluated by whether the patients achieve complete remission (CR) and partial remission (PR) after chemotherapy.

Results

There were 69 TNBCs in the 629 patients with breast cancer. The premenopausal patients, which was found in 49/69 of TNBCs, was more than NTNBCs. The average diameter of tumor in TNBC group was 4.1 cm, lager than NTNBC group. TNBC with axillary nodes metastasis occurred in 21 cases, and the axillary nodes metastasis rate was lower than NTNBC. The positive expression rate of p53 in TNBC was 44.9%, and the overall response (CR+PR) was 72.2%. No statistical differences were found regarding the positive expression rate of p53 and the overall response between TNBC and NTNBC.

Conclusion

TNBC were a group of primary breast cancers with triple negative, tending to occur in premenopausal women, with larger tumors, lower axillary nodes metastasis rate. TNBC had worse clinical prognosis and currently lacked effective targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? [J]. J Clin Oncol 2005; 23:7350–7360.

    Article  CAS  PubMed  Google Scholar 

  2. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [J]. Cancer 2007; 109:25–32.

    Article  CAS  PubMed  Google Scholar 

  3. Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 [J]. Breast Cancer Res 2006; 8:R66.

    Article  PubMed  Google Scholar 

  4. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J]. Clin Cancer Res 2007; 13(15 Pt 1): 4429–4434.

    Article  PubMed  Google Scholar 

  5. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry [J]. Cancer 2007; 109: 1721–1728.

    Article  PubMed  Google Scholar 

  6. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer [J]. J Clin Oncol 2006; 24:5652–5657.

    Article  PubMed  Google Scholar 

  7. Rodríquez-Pinilla SM, Sarrió D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas [J]. Clin Cancer Res 2006; 12:1533–1539.

    Article  Google Scholar 

  8. Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients [J]. Breast Cancer Res Treat 2008; 111:27–44.

    Article  CAS  PubMed  Google Scholar 

  9. James CR, Quinn JE, Mullan PB, et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer [J]. Oncologist 2007; 12: 142–150.

    Article  CAS  PubMed  Google Scholar 

  10. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J]. JAMA 2006; 295:2492–2502.

    Article  CAS  PubMed  Google Scholar 

  11. Yuli C, Shao N, Rao R, et al. BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers [J]. Oncogene 2007; 26: 6031–6037.

    Article  CAS  PubMed  Google Scholar 

  12. Moyano JV, Evans JR, Chen F, et al. Alpha B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer [J]. J Clin Invest 2006; 116:261–270.

    Article  CAS  PubMed  Google Scholar 

  13. Pinilla SM, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer [J]. Breast Cancer Res Treat 2006; 99:85–90.

    Article  CAS  PubMed  Google Scholar 

  14. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies [J]. Breast 2007; 16: 104–107.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chongqing Cancer Institute, Chongqing, 400030, China

    Xin Zhou & Qian Liu

Authors
  1. Xin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xin Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, X., Liu, Q. Clinicopathological characters of triple negative breast cancer. Chin. J. Cancer Res. 22, 17–20 (2010). https://doi.org/10.1007/s11670-010-0017-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-010-0017-8

Key words

CLC number

Search

Navigation